Hepatitis C summary
ASHM Regional Advisory Group interim HCV recommendations
Prepared by: Dr. Robert Batey, and members of the Taskforce and Regional Advisory Group viral hepatitis sub-groups
UPDATED ON: 17 June 2020
Disclaimer: The recommendations provided are the opinions of the authors and are not intended to provide a standard of care, or practice. This document does not reflect a systematic review of the evidence but will be revised to include relevant future systematic review findings. The recommendations are not intended to replace national guidance.
Evidence is limited and emerging. Currently it appears that:
People living with HCV who may be at increased risk of severe COVID:
People with HCV without cirrhosis: defer HCV treatment and investigation if risk of secondary transmission is low
People with cirrhosis: treatment and investigation should continue as planned
Patients receiving HCV treatment:
Check vaccinations: Influenza Pneumococcal
Optimise health and comorbidities.
Check Psychosocial status: connect patients to available services
Connect with Community based organisations (CBOs)
Adhere to measures that reduce COVID infection
Social/physical distancing: adhere to local guidelines